Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:東京大学医学部附属病院(以下,当院)における2019〜2021年のぶどう膜炎初診患者の統計調査。
対象と方法:上記期間に当院を初診したぶどう膜炎患者520例を対象とした。診療録をもとに,年齢,性別,罹患眼,解剖学的病変部位,診断名などについて検討を行った。過去の当院の統計結果,全国疫学調査の結果と比較した。
結果:初診時平均年齢54.1±20.0歳,男性223例(42.9%),女性297例(57.1%)であった。両眼性307例(59.0%),片眼性213例(41.0%)であった。前部ぶどう膜炎206例(39.6%),中間部ぶどう膜炎16例(3.1%),後部ぶどう膜炎74例(14.2%),汎ぶどう膜炎224例(43.1%)であった。診断がついた症例は353例(67.9%)であり,サルコイドーシス51例(9.8%),ヘルペス性虹彩炎37例(7.1%),急性前部ぶどう膜炎36例(6.9%),眼内悪性リンパ腫34例(6.5%),Vogt-小柳-原田病24例(4.6%),ベーチェット病23例(4.4%),の順であった。抗腫瘍薬関連の薬剤性ぶどう膜炎を8例(1.5%)に認めた。
結論:2016〜2018年の当院の統計結果と比較し,原因疾患の傾向はほぼ同じであった。全国疫学調査と比較し,当院では眼内悪性リンパ腫が多い結果であった。抗腫瘍薬関連の薬剤性ぶどう膜炎症例が増加しており,今後も増加が予想される。
Abstract Purpose:To investigate the clinical and demographic factors of patients with uveitis from 2019 to 2021 at the University of Tokyo Hospital.
Subjects and Methods:We reviewed the clinical records of patients who presented with uveitis at the University of Tokyo Hospital from January 2019 to December 2021. We analyzed data regarding the age, sex, laterality, anatomical classification, and diagnosis of these patients. We compared the results of this study with the results of previous epidemiologic studies and with those of our hospital.
Results:The study comprised 520 patients of which 297 were female(57.1%)and 223 were male(42.9%). The mean age at the initial visit was 54.1±20.0 years. Overall, there were 307(59.0%)bilateral cases and 213(41.0%)unilateral cases. Panuveitis was the most predominant mode of presentation(224 cases, 43.1%), followed by anterior uveitis(206 cases, 39.6%), posterior uveitis(74 cases, 14.2%), and intermediate uveitis(16 cases, 3.1%). The most common diagnoses were sarcoidosis(9.8%), herpetic iridocyclitis(7.1%), acute anterior uveitis(6.9%), intraocular malignant lymphoma(6.5%), Vogt-Koyanagi-Harada disease(4.6%), and Behçet's disease(4.4%).
Conclusion:Compared to our statistical results from 2016-2018, the trends of causative diseases were similar. The number of cases of drug-induced uveitis related to antitumor drugs has increased and is expected to continue to increase.
Copyright © 2023, Igaku-Shoin Ltd. All rights reserved.